Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
34 articles with Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Company will release its first quarter 2018 financial results and provide a corporate update on Tuesday, May 8, 2018, after the close of the U.S. financial markets
Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
- Arena's non-core, proprietary, preclinical compound provides strategic fit with Outpost Medicine's expertise in developing products for genitourinary disorders
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that data from a post-hoc analysis of the 22-week Phase 2 clinical study for its investigative drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH), will be presented at the International Society for Heart and Lung Transplantation (ISHLT) 2018 Annual Meeting
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
Arena Pharmaceuticals is hoping to raise $352 million from a stock offering just days after releasing positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $41.50 per share.
Arena Pharmaceuticals released positive top-line results from its Phase II trial of etrasimod in ulcerative colitis.
Arena Pharmaceuticals, Inc. announced that it intends to offer and sell, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering.
Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
Arena Pharmaceuticals, Inc. announced positive topline Phase 2 results from the OASIS trial for etrasimod.
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
"We've made significant progress in 2017, achieving the clinical and corporate objectives we set forth as a new team," said Amit D. Munshi, president and CEO.
Arena Pharmaceuticals to Announce Fourth Quarter and Full-Year 2017 Financial Results and Provide Corporate Update on Wednesday, March 14
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), will announce its fourth quarter and full-year 2017 financial results on Wednesday, March 14, 2018, before the open of the U.S. financial markets.
Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn's Disease at American Pain Society Annual Scientific Summit
- Data from Phase 1 study of APD371 in healthy volunteers demonstrate safety and tolerability - Healthy volunteers did not exhibit psychotropic effects commonly seen with cannabinoids - Preclinical studies show thousand-fold selectivity for CB2 over CB1 receptors
Arena Pharma and Everest Medicines Enter Into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
Arena and Everest announced today that they have entered into a development and commercialization partnership for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea.
Arena today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis.